Premium
Utility of ultrasound‐guided liver tumor biopsy for next‐generation sequencing‐based clinical sequencing
Author(s) -
Eso Yuji,
Kou Tadayuki,
Nagai Hiroki,
Kim Young Hak,
Kanai Masashi,
Matsumoto Shigemi,
Mishima Masako,
Arasawa Soichi,
Iguchi Eriko,
Nakamura Fumiyasu,
Takeda Haruhiko,
Takai Atsushi,
Takahashi Ken,
Ueda Yoshihide,
Muto Manabu,
Seno Hiroshi
Publication year - 2019
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.13312
Subject(s) - biopsy , medicine , dna sequencing , liver biopsy , multiplex , liquid biopsy , cancer , pathology , gene , bioinformatics , biology , genetics
Aim Recent advances in next‐generation sequencing (NGS) technologies allow for evaluation of genetic alterations in various cancer‐related genes in daily clinical practice. Archival formalin‐fixed paraffin‐embedded (FFPE) tumor tissue is often used for NGS‐based clinical sequencing assays; however, the success rate of NGS assays using archival FFPE tumor tissue is reported to be lower than that using fresh tumor tissue. We aimed to evaluate the feasibility and safety of ultrasound (US)‐guided liver tumor biopsy for NGS‐based multiplex gene assays. Methods We compared the success rate of NGS assays between archival FFPE tumor tissues and US‐guided liver tumor biopsy tissues, and summarized the treatment progress of the patients. Results Next‐generation sequencing assays using US‐guided liver biopsy samples were successful in all patients (22/22), whereas the success rate with archival FFPE tumor tissue was 84.8% (151/178, P < 0.05). At least one potentially actionable genetic alteration was identified from the US‐guided liver biopsy samples in 20 of 22 patients. Among the 18 patients with actionable genetic alterations targetable with drugs approved by the US Food and Drug Administration, eight initiated mutation‐driven targeted therapies. Of these eight patients, four achieved partial response or stable disease for at least 4 months, and three were not assessable for response due to short exposure. There were no biopsy‐related complications requiring additional treatment. Conclusion Our findings suggest that US‐guided liver tumor biopsy is a useful and safe method for obtaining high‐quality samples for NGS‐based clinical sequencing. In cases with metastatic liver tumors, US‐guided biopsy should be considered to provide accurate and optimal sequencing results for patients.